empagliflozin + DPP-4 inhibitors

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Nov 16, 2016 โ†’ Mar 11, 2024

About empagliflozin + DPP-4 inhibitors

empagliflozin + DPP-4 inhibitors is a pre-clinical stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT03464045. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT03464045Pre-clinicalCompleted
NCT02864914Pre-clinicalCompleted